Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations - PubMed (original) (raw)
. 2006 Apr 20;24(12):1924-31.
doi: 10.1200/JCO.2005.04.4974. Epub 2006 Mar 27.
Christine Fuller, Twala L Hogg, James Dalton, David Finkelstein, Ching C Lau, Murali Chintagumpala, Adekunle Adesina, David M Ashley, Stewart J Kellie, Michael D Taylor, Tom Curran, Amar Gajjar, Richard J Gilbertson
Affiliations
- PMID: 16567768
- DOI: 10.1200/JCO.2005.04.4974
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations
Margaret C Thompson et al. J Clin Oncol. 2006.
Abstract
Purpose: Traditional genetic approaches to identify gene mutations in cancer are expensive and laborious. Nonetheless, if we are to avoid rejecting effective molecular targeted therapies, we must test these drugs in patients whose tumors harbor mutations in the drug target. We hypothesized that gene expression profiling might be a more rapid and cost-effective method of identifying tumors that contain specific genetic abnormalities.
Materials and methods: Gene expression profiles of 46 samples of medulloblastoma were generated using the U133av2 Affymetrix oligonucleotide array and validated using real-time reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry. Genetic abnormalities were confirmed using fluorescence in situ hybridization (FISH) and direct sequencing.
Results: Unsupervised analysis of gene expression profiles partitioned medulloblastomas into five distinct subgroups (subgroups A to E). Gene expression signatures that distinguished these subgroups predicted the presence of key molecular alterations that we subsequently confirmed by gene sequence analysis and FISH. Subgroup-specific abnormalities included mutations in the Wingless (WNT) pathway and deletion of chromosome 6 (subgroup B) and mutations in the Sonic Hedgehog (SHH) pathway (subgroup D). Real-time RT-PCR analysis of gene expression profiles was then used to predict accurately the presence of mutations in the WNT and SHH pathways in a separate group of 31 medulloblastomas.
Conclusion: Genome-wide expression profiles can partition large tumor cohorts into subgroups that are enriched for specific genetic alterations. This approach may assist ultimately in the selection of patients for future clinical trials of molecular targeted therapies.
Similar articles
- FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM. Remke M, et al. J Clin Oncol. 2011 Oct 10;29(29):3852-61. doi: 10.1200/JCO.2011.36.2798. Epub 2011 Sep 12. J Clin Oncol. 2011. PMID: 21911727 - Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis.
Hui AB, Takano H, Lo KW, Kuo WL, Lam CN, Tong CY, Chang Q, Gray JW, Ng HK. Hui AB, et al. Clin Cancer Res. 2005 Jul 1;11(13):4707-16. doi: 10.1158/1078-0432.CCR-05-0128. Clin Cancer Res. 2005. PMID: 16000565 - C-kit expression and mutational analysis in medulloblastoma.
Chilton-Macneill S, Ho M, Hawkins C, Gassas A, Zielenska M, Baruchel S. Chilton-Macneill S, et al. Pediatr Dev Pathol. 2004 Sep-Oct;7(5):493-8. doi: 10.1007/s10024-004-1116-7. Epub 2004 Jul 30. Pediatr Dev Pathol. 2004. PMID: 15547773 - Medulloblastoma molecular dissection: the way toward targeted therapy.
Remke M, Ramaswamy V, Taylor MD. Remke M, et al. Curr Opin Oncol. 2013 Nov;25(6):674-81. doi: 10.1097/CCO.0000000000000008. Curr Opin Oncol. 2013. PMID: 24076581 Review. - FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma.
Ramaswamy V, Northcott PA, Taylor MD. Ramaswamy V, et al. Cancer Genet. 2011 Nov;204(11):577-88. doi: 10.1016/j.cancergen.2011.11.001. Cancer Genet. 2011. PMID: 22200083 Review.
Cited by
- Genetic grouping of medulloblastomas by representative markers in pathologic diagnosis.
Min HS, Lee JY, Kim SK, Park SH. Min HS, et al. Transl Oncol. 2013 Jun 1;6(3):265-72. doi: 10.1593/tlo.12382. Print 2013 Jun. Transl Oncol. 2013. PMID: 23730405 Free PMC article. - Identification of small molecule activators of BMP signaling.
Vrijens K, Lin W, Cui J, Farmer D, Low J, Pronier E, Zeng FY, Shelat AA, Guy K, Taylor MR, Chen T, Roussel MF. Vrijens K, et al. PLoS One. 2013;8(3):e59045. doi: 10.1371/journal.pone.0059045. Epub 2013 Mar 19. PLoS One. 2013. PMID: 23527084 Free PMC article. - Molecular Classification of Medulloblastoma.
Kijima N, Kanemura Y. Kijima N, et al. Neurol Med Chir (Tokyo). 2016 Nov 15;56(11):687-697. doi: 10.2176/nmc.ra.2016-0016. Epub 2016 May 26. Neurol Med Chir (Tokyo). 2016. PMID: 27238212 Free PMC article. Review. - GANT61 Reduces Hedgehog Molecule (GLI1) Expression and Promotes Apoptosis in Metastatic Oral Squamous Cell Carcinoma Cells.
Bacelar Sacramento de Araújo T, de Oliveira Siquara da Rocha L, Torres Andion Vidal M, Cerqueira Coelho PL, Galvão Dos Reis M, Solano de Freitas Souza B, Botelho Pereira Soares M, Almeida Pereira T, Della Coletta R, Pereira Bezerra D, Borges Dias R, Araújo Gurgel Rocha C. Bacelar Sacramento de Araújo T, et al. Int J Mol Sci. 2020 Aug 24;21(17):6076. doi: 10.3390/ijms21176076. Int J Mol Sci. 2020. PMID: 32846867 Free PMC article. - Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA. Swartling FJ, et al. Cancer Cell. 2012 May 15;21(5):601-613. doi: 10.1016/j.ccr.2012.04.012. Cancer Cell. 2012. PMID: 22624711 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources